Brain Energy Metabolism in Alzheimers Disease - Part C
- 1st Edition, Volume 188 - September 1, 2026
- Latest edition
- Editor: Subashchandrabose Chinnathambi
- Language: English
Brain Energy Metabolism in Alzheimer’s Disease – Part C, Volume 188 in the International Review of Neurobiology series, presents the latest research on metabolic dysfunction and it… Read more
Description
Description
Brain Energy Metabolism in Alzheimer’s Disease – Part C, Volume 188 in the International Review of Neurobiology series, presents the latest research on metabolic dysfunction and its role in neurodegenerative diseases. This volume brings together contributions from an international panel of experts, exploring the molecular, cellular, and systemic aspects of energy metabolism in Alzheimer’s disease and related disorders.
Chapters in this release examine metabolic therapeutic targets in Alzheimer’s disease, alterations in brain energy metabolism in comparison with Parkinson’s disease, and the role of epigenetic modulation through natural compounds. Additional sections address mitochondrial dysfunction, disruption of metabolic pathways, and the contribution of glial cells to neurodegenerative processes.
Further contributions explore metabolic disorders linked to Parkinson’s disease, signaling pathways in neurodegeneration, and advances in therapeutic and diagnostic strategies targeting key enzymes. The volume also highlights the role of intestinal microbiota, nanocarrier-based therapeutic approaches, and emerging treatments such as HDAC inhibitors. Together, these chapters provide a comprehensive overview of the mechanisms, biomarkers, and therapeutic prospects related to energy metabolism in neurodegenerative diseases, making this volume an essential reference for researchers and clinicians in neuroscience and neurobiology.
Key features
Key features
- Presents current advances in brain energy metabolism and neurodegenerative disease research
- Includes contributions from leading experts in neuroscience, neurobiology, and metabolic research
- Covers molecular, cellular, and systemic aspects of metabolic dysfunction in Alzheimer’s disease
- Explores therapeutic targets, diagnostic approaches, and emerging treatment strategies
- Serves as an essential reference for researchers, clinicians, and graduate students
Readership
Readership
Table of contents
Table of contents
Part C
- Metabolic Therapeutic Targets in Alzheimer’s Disease (AD)
- Brain Energy Metabolism Changes and Neuropsychological Impairment in Parkinson Disease vs Alzheimer’s Disease
- Modulation of Epigenetic Effect in Alzheimer’s Disease via Natural Compounds
- Energetic Crisis, Mitochondrial Vulnerability and Disruption of Lactate Shuttle in Alzheimer’s Disease
- Astroglial Dysregulation and Gliotransmitter Imbalance in Schizophrenia
- Metabolic Disorders and Parkinson’s Disease
- Molecular Insights of PPAR-γ Signalling in Amyotrophic Lateral Sclerosis and Huntington’s Disease
- A Comprehensive Review on Therapeutics and Diagnostic Agents Targeting Acetyl and Butyryl Cholinesterases for AD
- Intestinal Microbiota in Neurodegeneration and Ageing
- Chapter Title to Be Determined
- Brain Energy Crisis in Alzheimer’s and Parkinson’s Disease: Can Nanocarriers Offer a Therapeutic Breakthrough?
- The Potential of HDAC Inhibitors for Alzheimer’s Disease
- The Tau–Mitochondria Connection and Its Impact on Cellular Energy Metabolism in Alzheimer’s Disease
- Brain Lipid Dysregulation as a Driver of Energy Metabolism Failure in Alzheimer’s Disease
- Metabolic Dysregulation in Alzheimer’s Disease: Mechanisms, Markers, and Therapeutic Prospects
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 188
- Published: September 1, 2026
- Language: English
About the editor
About the editor
SC
Subashchandrabose Chinnathambi
Subashchandrabose Chinnathambi is Additional Professor at the Department of Neurochemistry, National Institute of Mental Health and Neurosciences Hospital Bangalore, Karnataka, India. His scientific interests include physiopathology of neurodegenerative disorders, Tau Cytoskeleton, Tau-GPCR, purinergic and chemokine receptors, Tau stem cells, animal models, neuropharmacology, therapeutic approaches targeting Tau oligomers, and biomarkers for neurodegeneration. He serves on the editorial board for various international cell biology journals and is also a regular invited speaker at a number of meetings and workshops. Dr. Chinnathambi has more than 16 years of research experience in the area of neuroscience and Tau-related research in Alzheimer’s Disease.